

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
<u>正木康史</u>	血液・造血器の疾患 17-10. 白血球疾患 17-10-1. 総論	矢崎義雄、小室一成 総編集	内科学 第12版	朝倉書店	東京	2022	97-100
<u>正木康史</u>	Castleman病/TAFRO症候群	鈴木隆浩、竹中克斗、池添隆之 編集	専門医のための血液病学	医学書院	東京	2022	260-263
<u>古賀智裕</u> , <u>住吉玲美</u> , <u>川上純</u> .	キャッスルマン病の病因・病態.	吉崎和幸, 川上 純	キャッスルマン病, TAFRO症候群	フジメディカル出版	大阪	2022	13-19
<u>水木満佐央</u> .	キャッスルマン病の疫学, 発生率, 統計的事項 1) 全国調査.	吉崎和幸, 川上 純	キャッスルマン病, TAFRO症候群	フジメディカル出版	大阪	2022	20-24
<u>正木康史</u> , <u>川端浩</u> , <u>川野充弘</u> , <u>岩城憲子</u> , <u>鈴木律朗</u> .	キャッスルマン病の疫学, 発生率, 統計的事項 2) 定点観測 (石川県).	吉崎和幸, 川上 純	キャッスルマン病, TAFRO症候群	フジメディカル出版	大阪	2022	25-28
<u>佐藤康晴</u> .	キャッスルマン病の病理.	吉崎和幸, 川上 純	キャッスルマン病, TAFRO症候群	フジメディカル出版	大阪	2022	29-35
<u>正木康史</u> , <u>黒瀬望</u> , <u>川端浩</u> .	キャッスルマン病の関連疾患 4) その他の疾患 腫瘍, 膠原病.	吉崎和幸, 川上 純	キャッスルマン病, TAFRO症候群	フジメディカル出版	大阪	2022	134-141
<u>青木定夫</u> .	TAFRO症候群の定義, 概念.	吉崎和幸, 川上 純	キャッスルマン病, TAFRO症候群	フジメディカル出版	大阪	2022	144-149
<u>石垣靖人</u> , <u>中村有香</u> .	TARFO症候群の病因解明に向けて.	吉崎和幸, 川上 純	キャッスルマン病, TAFRO症候群	フジメディカル出版	大阪	2022	150-154
<u>黒瀬望</u> , <u>山田壮亮</u> .	TAFRO症候群の病理-リンパ節病変-.	吉崎和幸, 川上 純	キャッスルマン病, TAFRO症候群	フジメディカル出版	大阪	2022	155-159
<u>黒瀬望</u> , <u>山田壮亮</u> .	TAFRO症候群の検査成績 2) リンパ節外病変 ①TAFRO症候群の病理-骨髄病変-.	吉崎和幸, 川上 純	キャッスルマン病, TAFRO症候群	フジメディカル出版	大阪	2022	168-170
<u>古賀智裕</u> , <u>住吉玲美</u> , <u>川上純</u> .	キャッスルマン病およびTAFRO症候群の病因・病態探索に向けた試み.	吉崎和幸, 川上 純	キャッスルマン病, TAFRO症候群	フジメディカル出版	大阪	2022	212-216
<u>矢野真吾</u> .	本邦のキャッスルマン病の診療体制.	吉崎和幸, 川上 純	キャッスルマン病, TAFRO症候群	フジメディカル出版	大阪	2022	221-225

<u>井出 眞</u> .	国際キャッスルマン病研究組織 (CDCN).	吉崎和幸, 川上 純	キャッスルマン病, TAFRO症候群	フジメディカル出版	大阪	2022	226-231
<u>正木康史</u> , 上田祐輔, 柳澤浩人, 在田幸太郎, 坂井知之.	XI. 縦隔疾患Castleman病.		別冊 日本臨床領域別症候群シリーズNo. 21 呼吸器症候群 (第3版) —その他の呼吸器疾患を含めて—	日本臨床社	東京	2021	159-198
<u>佐藤康晴</u> .	第II編・第13章・造血器・リンパ組織.	金城満, 亀井敏昭, 樋口佳代子	細胞診鑑別アトラス	医歯薬出版	東京	2021	410

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
<u>古賀智裕</u> , 住吉玲美, 細萱直希, <u>川上 純</u> .	キャッスルマン病・TAFRO症候群レジストリ研究.	リウマチ科	64(9)	499-502	2023
<u>Masaki Y</u> , Ueda Y, Yanagisawa H, Arita K, Sakai T, Yamada K, Mizuta S, Fukushima T, Takai K, <u>Aoki S</u> , Kawabata H.	TAFRO Syndrome: A Disease Requiring Immediate Medical Attention.	Intern Med	62(1)	27-32	2023
Kawanishi M, Kamei F, Sonoda H, Oba M, Fukunaga S, Egawa M, Koyama T, <u>Sato Y</u> , Tanabe K, Ito T.	Utility of renal biopsy in differentiating idiopathic multicentric Castleman disease from IgG4-related disease.	CEN Case Rep	12(2)	242-248	2023
<u>佐藤康晴</u> .	idiopathic plasmacytic lymphadenopathy (IPL) が世界に認められるとき.	病理と臨床	41 (1)	100-102	2023
Sumiyoshi R, <u>Koga T</u> , <u>Kawakami A</u> .	Candidate Biomarkers for Idiopathic Multicentric Castleman Disease. J Clin Exp Hematop.	J Clin Exp Hematop	62(2)	85-90	2022
Nakayama Y, Mizuno H, <u>Sawa N</u> , Suwabe T, Yamanouchi M, Ikuma D, Hasegawa E, Hoshino J, Sekine A, Oba Y, Kono K, Kinowaki K, Ohashi K, Suzuki K, <u>Sato Y</u> , Shimizu A, Yamaguchi Y, Ubara Y.	A Case of Adolescent-onset TAFRO Syndrome with Malignant Nephrosclerosis-like Lesions.	Intern Med	Online ahead of print.		2022
西村碧フィリーズ, 錦織亜沙美, <u>佐藤康晴</u> .	Castleman病の歴史的背景とunicentric Castleman disease.	病理と臨床	40 (11)	1121-1127	2022

錦織亜沙美, 西村碧フィリーズ, <u>佐藤康晴</u> .	Idiopathic multicentric Castleman diseaseの分類と臨床病理学的特徴.	病理と臨床	40 (11)	1128-1133	2022
Nakayama Y, Mizuno H, Sawa N, Suwabe T, Yamanouchi M, Ikuma D, Hasegawa E, Hoshino J, Sekine A, Oba Y, Kono K, Kinowaki K, Ohashi K, Suzuki K, <u>Sato Y</u> , Shimizu A, Yamaguchi Y, Ubara Y.	A Case of Adolescent-onset TAFRO Syndrome with Malignant Nephrosclerosis-like Lesions.	Intern Med	Online ahead of print.		2022
Liu W, Cai Q, Yu T, Strati P, Hagemester FB, Zhai Q, Zhang M, Li L, Fang X, Li J, Sun R, Zhang S, Yang H, Wang Z, Qian W, <u>Iwaki N</u> , <u>Sato Y</u> , Oksenhendler E, Xu-Monette ZY, Young KH, Yu L.	Clinical characteristics and outcomes of Castleman disease: a multicenter Consortium study of 428 patients with 15-year follow-up.	Am J Cancer Res	12 (9)	4227-4240	2022
Nishikori A, Nishimura MF, Nishimura Y, Otsuka F, Maehama K, Ohsawa K, Momose S, <u>Nakamura N</u> , <u>Sato Y</u> .	Idiopathic plasmacytic lymphadenopathy forms an independent subtype of idiopathic multicentric Castleman disease.	Int J Mol Sci	23(18)	10301	2022
Nishimura Y, Nishimura MF, Fajgenbaum DC, van Rhee F, <u>Sato Y</u> , Otsuka F.	Global public awareness of Castleman disease and TAFRO syndrome between 2015 and 2021: A Google Trends analysis.	eJHaem	3(3)	748-753	2022
Nishimura MF, Nishimura Y, Nishikori A, Yoshino T, <u>Sato Y</u> .	Historical and pathological overview of Castleman disease.	J Clin Exp Hematop	62(2)	60-72	2022
Nishimura Y, Nishimura MF, <u>Sato Y</u> .	International definition of iMCD-TAFRO: future perspectives.	J Clin Exp Hematop	62(2)	73-78	2022
Nishimura Y, Nishikori A, Sawada H, Czech T, Otsuka Y, Nishimura MF, Mizuno H, Sawa N, Momose S, Ohsawa K, Otsuka F, <u>Sato Y</u> .	Idiopathic multicentric Castleman disease with positive antiphospholipid antibody: atypical and undiagnosed autoimmune disease ?	J Clin Exp Hematop	108(4)	354-355	2022
<u>Ide M</u> , Ohnishi H, Fukumoto T, Ohno H, Yokoyama T.	Re-evaluation of rituximab therapy for idiopathic Castleman disease: Retrospective study from single-center experience.	Eur J Haematol	108	354-355	2022
Inano T, Yasuda H, Tsukune Y, Wali N, Saeki H, Kajino K, Hino O, <u>Masaki Y</u> , Komatsu N.	Abnormal exacerbation of moderately differentiated gastric adenocarcinoma in a patient with TAFRO syndrome: an impaired tumor immunity?	Case Rep Oncol	15(1)	7-11	2022

Yanagisawa H, Kawabata H, Ueda Y, Arita K, Iwao-Kawanami H, Sakai T, Kawanami T, Yamada K, Mizuta S, Fukushima T, Masaki Y.	Prognostic impacts of serum levels of C-reactive protein, albumin, and total cholesterol in patients with myelodysplastic syndromes.	Int J Hematol	116(1)	81-88.	2022
Miyazaki K, Suzuki R, Oguchi M, Taguchi S, Amaki J, Maeda T, Kubota N, Maruyama D, Terui Y, Sekiguchi N, Takizawa J, Tsukamoto H, Murayama T, Ando T, Matsuoka H, Hasegawa M, Wada H, Sakai R, Kameoka Y, Tsukamoto N, Choi I, Masaki Y. , Shimada K, Fukuhara N, Utsumi T, Uoshima N, Kagami Y, Asano N, Ejima Y, Katayama N, Yamaguchi M.	Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma.	Hematol Oncol	40(4)	667-677	2022
Masaki Y. , Arita K, Sakai T, Takai K, Aoki S. , Kawabata H.	Castleman disease and TAFRO syndrome.	Annals of Hematology	101(3)	485-490	2022
Kawakita E, Yang F, Kumagai A, Kitada M, Yoshitomi Y, Ikeda T, Nakamura Y, Ishigaki Y. , Kanasaki K, Koya D.	Metformin Mitigates DPP-4 Inhibitor-Induced Breast Cancer Metastasis via Suppression of mTOR Signaling.	Mol Cancer Res	19(1)	61-73	2021
佐藤康晴 , 錦織亜沙美, 西村碧フィリーズ	特発性多中心性キャッスルマン病とIPL	病理と臨床	39(9)	938-940	2021
井出 眞 , 西岡 聡, ほか.	キャッスルマン病：トシリズマブ	腎と透析 91巻増刊号 腎疾患治療薬update	91	168-171	2021
住吉玲美, 川上 純 , ほか.	病態理解に沿った治療選択. IL-6阻害薬・キャッスルマン病.	生物学的製剤適性使用ガイド			2021
Sumiyoshi R, Koga T. , Furukawa K, Umeda M, Yamamoto K, Mori R, Kawakami A.	A case of tocilizumab-refractory idiopathic multicentric Castleman's disease successfully treated with sirolimus.	Clin Immunol	233	10888	2021
Endo Y, Koga T. , Ubara Y, Sumiyoshi R, Furukawa K, Kawakami A.	Mediterranean Fever gene variants confer susceptibility to and modify clinical phenotypes of idiopathic multicentric Castleman disease.	Clin Exp Immunol	206(1)	91-98	2021

Kawabata H, Fujimoto S, Sakai T, Yanagisawa H, Kitawaki T, Nara K, Hagihara M, Yamamoto H, Tanimizu M, Kato C, Origuchi T, Sunami K, Sunami Y, Masunari T, Nakamura N, Kobayashi M, Yamagami K, Miura K, Takai K, <u>Aoki S</u> , Tsukamoto N, <u>Masaki Y</u> .	Correction to: Patient's age and D-dimer levels predict the prognosis in patients with TAFRO syndrome.	Int J Hematol	14(2)	301-302	2021
Fujimoto S, Kawabata H, Sakai T, Yanagisawa H, Nishikori M, Nara K, Ohara S, Tsukamoto N, Kurose N, <u>Yamada S</u> , Takai K, <u>Aoki S</u> , <u>Masaki Y</u> .	Optimal treatments for TAFRO syndrome: a retrospective surveillance study in Japan.	Int J Hematol	113	73-80	2021
Pierson SK, Shenoy S, Oromendia AB, Gorzewski AM, Langan Pai RA, Nabel CS, Ruth JR, Parente SAT, Arenas DJ, Guilfoyle M, Reddy M, Weinblatt M, Shadick N, Bower M, Prida AD, <u>Masaki Y</u> , Katz L, Mezey J, Beineke P, Lee D, Tendler C, Kambayashi T, Fosså A, van Rhee F, Fajgenbaum DC.	Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease.	Blood Advances	5(17)	3445-3456	2021
Kawabata H, Fujimoto S, Sakai T, Yanagisawa H, Kitawaki T, Nara K, Hagihara M, Yamamoto H, Tanimizu M, Kato C, Origuchi T, Sunami K, Sunami Y, Masunari T, Nakamura N, Kobayashi M, Yamagami K, Miura K, Takai K, <u>Aoki S</u> , Tsukamoto N, <u>Masaki Y</u> .	Patient's age and D-dimer levels predict the prognosis in patients with TAFRO syndrome.	Int J Hematol	114(2)	179-188	2021
Shirai Y, Fukue R, <u>Kaneko Y</u> , Kuwana M.	Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease.	Diagnosics (Basel)	11(11)	2007	2021
Gion Y, Doi M, Nishimura Y, Ikeda T, Nishimura MF, Sakamoto M, Egusa Y, Nishikori A, Fujita A, <u>Iwaki N</u> , <u>Nakamura N</u> , Yoshino T, <u>Sato Y</u> .	PD-L1 expression is associated with the spontaneous regression of patients with methotrexate-associated lymphoproliferative disorders.	Cancer Med	11(2)	417-432	2021

Nishikori A, Nishimura MF, Nishimura Y, Notohara K, Satou A, Moriyama M, Nakamura S, <u>Sato Y.</u>	Investigation of IgG4-positive cells in idiopathic multicentric Castleman disease and validation of the 2020 exclusion criteria for IgG4-related disease.	Pathol Int	72(1)	43-52	2021
Nishimura MF, Nishimura Y, Nishikori A, Maekawa Y, Maehama K, Yoshino T, <u>Sato Y.</u>	Clinical and pathological characteristics of hyaline-vascular type unicentric Castleman disease: a 20-year retrospective analysis.	Diagnos tics	11(1)	2008	2021
Nishimura Y, Fajgenbaum DC, Pierson SK, <u>Iwaki N.</u> , Nishikori A, Kawano M, <u>Nakamura N.</u> , Izutsu K, Takeuchi K, Nishimura MF, Maeda Y, Otsuka F, Yoshizaki K, Oksenhendler E, van Rhee F, <u>Sato Y.</u>	Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease.	Am J Hematol	96(10)	1241-1252	2021
Tosaki T, Okabe M, Suzuki T, Shimizu A, Koike K, Tsuboi N, Kawamura T, Ohashi R, <u>Yano S.</u> Yokoo T.	Membranous nephropathy with thrombotic microangiopathy-like lesions successfully treated with tocilizumab in a patient with idiopathic multicentric Castleman disease.	CEN CaseRep	10(2)	265-272	2021
Nishikori A, Nishimura Y, Shibata R, Ohshima K, Gion Y, Ikeda T, Nishimura MF, Yoshino T, <u>Sato Y.</u>	Upregulated expression of activation-induced cytidine deaminase in ocular adnexal marginal zone lymphoma with IgG4-positive cells.	Int J Mol Sci	22	4083	2021
Matsuo T, Tanaka T, <u>Sato Y.</u> , Kataoka H, Uka M, Ennishi D, Yano T.	Follow-up with serum IgG4-monitoring in 8 patients with IgG4-related disease diagnosed by a lacrimal gland mass.	J Clin Exp Hematop	61(1)	10-21	2021
Saito-Takatsuji H, Yoshitomi Y, <u>Ishigaki Y.</u> , Yamamoto S, Numata N, Sakai Y, Takeuchi M, Tomosugi N, Katsuda S, Yonekura H, Ikeda T.	Protective Effects of Collagen Tripeptides in Human Aortic Endothelial Cells by Restoring ROS-Induced Transcriptional Repression.	Nutrient s	13(7)	2226	2021
Kawanami T, Kawanami-Iwao H, Takata T, <u>Ishigaki Y.</u> , Tomosugi N, Takegami T, Yanagisawa H, Fujimoto S, Sakai T, Fujita Y, Yamada K, Mizuta S, Kawabata H, Fukushima T, Hirose Y, Masaki Y.	Comprehensive analysis of protein-expression changes specific to immunoglobulin G4-related disease.	Clin Chim Acta	523	45-57	2021

<u>Masaki Y</u> , Kawabata H, Takai K, Tsukamoto N, Fujimoto S, <u>Ishigaki Y</u> , Kurose N, Miura K, Nakamura S, <u>Aoki S</u> .	2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome.	Int J Hematol	111	155-158	2020
<u>正木康史</u> , 藤本信乃, 柳澤浩人, 坂井知之, 川端 浩.	Castleman病の診断と治療.	血液内科	82(1)	107-111	2021
<u>正木康史</u> , 坂井知之.	Castleman病とその周辺疾患.	Medical Practice	38(11)	1705-1707	2021
Kawano M, Hara S, Yachie A, <u>Sato Y</u> , Fajgenbaum DC.	HHV-8-negative multicentric Castleman disease patients with serological, histopathological and imaging features of IgG4-related disease.	Rheumatology (Oxford)	60(1)	e3-e4	2021
Endo Y, <u>Koga T</u> , Otaki H, Sasaki D, Sumiyoshi R, Furukawa K, Tanaka Y, Katsunori Y, <u>Kawakami A</u> .	Idiopathic multicentric Castleman disease with novel heterozygous Ile729Met mutation in exon 10 of familial Mediterranean fever gene.	Rheumatology (Oxford)	60(1)	445-450	2021
Mizuno H, <u>Sawa N</u> , Watanabe S, Ikuma D, Sekine A, Kawada M, Yamanouchi M, Hasegawa E, Suwabe T, Hoshino J, Takaichi K, Kinowaki K, Fujii T, Ohashi K, Nagata M, Yamaguchi Y, Ubara Y.	The Clinical and Histopathological Feature of Renal Manifestation of TAFRO Syndrome.	Kidney Int Rep	5(8)	1172-1179.	2020
Shiroshita K, Kikuchi T, Okayama M, Kasahara H, Kamiya T, Shimizu T, Kurose N, <u>Masaki Y</u> , Okamoto S.	Interleukin-6-producing Intravascular Large B-cell Lymphoma with Lymphadenopathy Mimicking the Histology of Multicentric Castleman Disease.	Intern Med	59(23)	3061-3065	2020
<u>佐藤康晴</u>	キャッスルマン病の歴史を振り返る.	病理と臨床	38(9)	848-852	2020
Nishimura MF, Igawa T, Gion Y, Tomita S, Inoue D, Izumozaki A, Ubara Y, Nishimura Y, Yoshino T, <u>Sato Y</u> .	Pulmonary manifestations of plasma cell type idiopathic multicentric Castleman disease: a clinicopathological study in comparison with IgG4-related disease.	J Pers Med	10	269	2020
Fajgenbaum DC, Wu D, Goodman A, Wong R, Chadburn A, Nasta S, Srkalovic G, Mukherjee S, Leitch H, Jayanthan R, Ferrero S, <u>Sato Y</u> , Schey S, Dispenzieri A, Oksenhendler E, Zinzani PL, Lechowicz MJ, Hoffmann C, Pemmaraju N, Bagg A, Fossa A, Lim MS, van Rhee F.	Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease.	Am J Hematol	95(12)	1553-1561	2020

Yu L, Shi M, Cai QQ, Strati P, Hagemester F, Zhai QL, Li L, Fan X, Li J, Sun R, Zhang S, Yang H, Wang Z, Qian W, Iwaki N, <u>Sato Y</u> , Zhang L, Li J, Oksenhendler E, Xu-Monette ZY, Young KH.	A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study.	Oncologist	25(11)	963-973	2020
Hasegawa K, Hanayama Y, Obika M, Miyoshi T, Ogawa H, Kondo E, Kataoka H, <u>Sato Y</u> , Otsuka F.	Clinical and biochemical characteristics of patients having general symptoms with increased serum IgG4.	Mod Rheumatol	30(4)	721-728	2020
Satou A, Notohara K, Zen Y, Nakamura S, Yoshino T, Okazaki K, <u>Sato Y</u> .	Clinicopathological differential diagnosis of IgG4-related disease: A historical overview and a proposal of the criteria for excluding mimickers of IgG4-related disease.	Pathol Int	70(7)	391-402	2020
Han Y, Igawa T, Ogino K, Nishikori A, Gion Y, Yoshino T, <u>Sato Y</u> .	Hemosiderin deposition in lymph nodes of patients with plasma cell-type Castleman disease.	J Clin Exp Hematop	60(1)	1-6	2020
van Rhee F, Oksenhendler E, Srkalovic G, Voorhees P, Lim M, Dispenzieri A, <u>Ide M</u> , Parente S, Schey S, Streetly M, Wong R, Wu D, Maillard I, Brandstadter J, Munshi N, Bowne W, Elenitoba-Johnson KS, Fössa A, Lechowicz MJ, Chandrakasan S, Pierson SK, Greenway A, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Chadburn A, Fajgenbaum DC.	International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.	Blood Adv	3(4)	6039-6050	2020
川端 浩, 藤本信乃, 吉藤元, 黒瀬 望, <u>山田壮亮</u> , <u>矢野真吾</u> , <u>川上 純</u> , 吉崎和幸, <u>正木康史</u> .	キャッスルマン病の診断と治療のガイドライン.	血液内科	82(3)	394-401	2020
Endo Y, <u>Koga T</u> , Umeda M, Furukawa K, Takenaka M, <u>Kawakami A</u> .	Successful canakinumab treatment for activated innate response in idiopathic Castleman's disease with multiple heterozygous MEFV exon 2 variants.	Clin Immunol	219	108547	2020
佐々木祥, <u>中山健夫</u> .	GRADEシステムによる診療ガイドライン.	腫瘍内科	26(3)	341-346	2020